Public Citizen seeks Avandia ban
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's troubled diabetes drug Avandia (rosiglitazone) is coming under renewed pressure after the US public interest group Public Citizencalled upon the US FDA to ban the drug because of new safety concerns. The move comes just days after a panel of experts representing the American Diabetes Association and the European Association for the Study of Diabetes issued revised treatment recommendations for type 2 diabetes in which they advise against using the product.